NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
2021 · Journal of the National Comprehensive Cancer Network · 327 citations
https://doi.org/10.6004/jnccn.2021.0018
K
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
267
Papers
8.3K
Citations
41
h-index
87
i10-index
Kari Kendra is an academic researcher from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & Immune cells in cancer. The author has an h-index of 41, co-authored 227 publications.
ORCID: 0000-0001-5936-6689Papers by this author
worksPhase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
2019 · Journal of Clinical Oncology · 173 citations
https://doi.org/10.1200/jco.19.01381
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
2021 · Journal for ImmunoTherapy of Cancer · 140 citations
https://doi.org/10.1136/jitc-2021-002478
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
2022 · The Lancet · 126 citations
https://doi.org/10.1016/s0140-6736(22)01659-2
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
2024 · Journal of the National Comprehensive Cancer Network · 100 citations
https://doi.org/10.6004/jnccn.2024.0036
Prognostic Gene Expression Profiling in Cutaneous Melanoma
2020 · JAMA Dermatology · 88 citations
https://doi.org/10.1001/jamadermatol.2020.1729
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat